Modified Bovine G-CSF Polypeptides for Non-Antibiotic Cattle Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mastitis and bovine respiratory disease in cattle, such as antibiotics, are not entirely satisfactory due to resistance issues and skin irritation, and there is a need for cost-effective non-antibiotic alternatives that effectively modulate the incidence, recurrence, and severity of these diseases.
Innovation Solution
Development of bovine granulocyte-colony stimulating factor (bG-CSF) polypeptides modified with non-naturally-encoded amino acids to enhance neutrophil function and immune response, potentially reducing bacterial infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotic therapy is used to treat bovine mastitis and respiratory disease, then disease treatment effectiveness is improved, but bacterial resistance and skin irritation occur
Solution Approach 1:
The patent modifies the amino acid sequence parameters of bovine G-CSF by incorporating non-naturally encoded amino acids at specific positions (e.g., positions 3, 7, 11, 33, 43, 58, 62, 67, 69, 98, 99, 123, 124, 133, 134, 141, 166, 169, 170, 173). These sequence parameter changes alter the protein's biological properties to enhance therapeutic efficacy while reducing harmful effects such as bacterial resistance and skin irritation associated with conventional antibiotic therapy.
Solution Approach 2:
The patent creates a composite molecular structure by combining bovine G-CSF polypeptide with non-naturally encoded amino acids and potentially linking to water-soluble polymers like polyethylene glycol. This composite approach integrates the therapeutic benefits of G-CSF with the advantageous properties of modified amino acids and polymers to achieve improved stability, solubility, and therapeutic efficacy without the harmful effects of traditional antibiotics.
2Reliability
If conventional bG-CSF is used, then therapeutic activity is maintained, but stability and therapeutic half-life are insufficient
Solution Approach 1:
The patent changes the amino acid sequence parameters by incorporating non-naturally encoded amino acids that can modify the protein's pharmacokinetic properties. These parameter changes are designed to extend the therapeutic half-life while maintaining biological activity, addressing the insufficiency of conventional bG-CSF duration of action.
Solution Approach 2:
The patent introduces water-soluble polymers such as polyethylene glycol as intermediary molecules that can be linked to the bG-CSF polypeptide. These polymer intermediaries act as carriers that extend the circulation time and half-life of the therapeutic protein in the body while maintaining its biological activity, thereby solving the duration of action problem.
3Stability of the object's composition
If bG-CSF polypeptides are modified with non-naturally encoded amino acids, then stability and solubility are improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies local quality modification by incorporating non-naturally encoded amino acids at specific, predetermined positions in the bG-CSF sequence rather than uniformly throughout the protein. This localized approach targets specific regions to improve stability and solubility while minimizing the overall complexity of the manufacturing process by limiting modifications to key positions only.
Data Source
AI summary
Modified bovine G-CSF polypeptides and uses thereof are provided.